Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Launched by UNIVERSITY HOSPITAL, BONN · Jun 7, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how CAR T-cell therapy, a new treatment for certain types of blood cancers, might affect the heart. CAR T-cell therapy helps the body fight cancer by using specially modified immune cells. While this treatment can be very effective, it can also cause side effects, including a serious condition called cytokine release syndrome, which may lead to heart inflammation (myocarditis). This study will use cardiac MRI, a type of imaging that looks at the heart, to better understand these potential effects on heart health in patients receiving CAR T-cell therapy.

To be eligible for the study, participants need to be adults who are undergoing CAR T-cell therapy and willing to give their consent to join. However, some individuals may not qualify if they have certain heart conditions, cannot have an MRI due to medical devices, are pregnant or breastfeeding, or have severe kidney problems. Those who take part can expect to undergo MRI scans to help researchers gather important information about how their heart responds to the treatment. This study is currently recruiting participants, and it represents an important step in understanding how CAR T-cell therapy affects not just cancer, but overall health, particularly heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing CAR T-cell therapy
• • Consent to participate in study
• Exclusion Criteria:
• • Inability to undergo MRI examinations due to large metallic implants, cardiac pacemakers/neurostimulators, or claustrophobia
• • Known cardiac conditions such as status post heart attack or myocarditis, complex congenital heard disease, or cardiomyopathies.
• • Birth control using an IUD.
• • Pregnancy or breastfeeding.
• • Renal insufficiency with a GFR below 30 ml/min/1.73m2